Cargando…

SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

OBJECTIVE: To study the association between insulin receptors (isoforms α and β), insulin growth factor‐1 (IGF1) and serine/arginine splicing factor 1 (SRSF‐1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS: We retrospectively analyzed data from 368 patients who underwent...

Descripción completa

Detalles Bibliográficos
Autores principales: Broggi, Giuseppe, Lo Giudice, Arturo, Di Mauro, Marina, Asmundo, Maria Giovanna, Pricoco, Elisabetta, Piombino, Eliana, Caltabiano, Rosario, Morgia, Giuseppe, Russo, Giorgio Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362056/
https://www.ncbi.nlm.nih.gov/pubmed/34196424
http://dx.doi.org/10.1002/pros.24185
_version_ 1783738076949905408
author Broggi, Giuseppe
Lo Giudice, Arturo
Di Mauro, Marina
Asmundo, Maria Giovanna
Pricoco, Elisabetta
Piombino, Eliana
Caltabiano, Rosario
Morgia, Giuseppe
Russo, Giorgio Ivan
author_facet Broggi, Giuseppe
Lo Giudice, Arturo
Di Mauro, Marina
Asmundo, Maria Giovanna
Pricoco, Elisabetta
Piombino, Eliana
Caltabiano, Rosario
Morgia, Giuseppe
Russo, Giorgio Ivan
author_sort Broggi, Giuseppe
collection PubMed
description OBJECTIVE: To study the association between insulin receptors (isoforms α and β), insulin growth factor‐1 (IGF1) and serine/arginine splicing factor 1 (SRSF‐1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS: We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor‐α and ‐β, IGF1 (IGF1‐R), Ki‐67, and prostate specific membrane antigen (PSMA) expression using validated score. RESULTS: The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF‐1 expression was associated with AR (odds ratio [OR]: 1.66), PSMA (OR: 2.13), Ki‐67 (OR: 5.99), insulin receptor (IR)‐α (OR: 2.38), IR‐β (OR: 3.48), IGF1‐R (OR: 1.53), and microvascular density (MVD) was associated with PSMA (OR: 3.44), Ki‐67 (OR: 2.23), IR‐α (OR: 2.91), IR‐β (OR: 3.02), IGF1‐R (OR: 2.95), and SRSF‐1 (OR: 2.21). In the sub cohort of PC patients, we found that SRSF‐1 expression was associated with AR (OR: 2.34), Ki‐67 (OR: 6.77), IR‐α (OR: 2.7), and MVD (OR: 1.98). At the Kaplan–Meier analysis, SRSF‐1(+) patients had worse 5‐ and 9‐year biochemical recurrence (36% and 6%) respect to SRSF‐1(−) (67% and 7%; p < .01) and similarly MVD(+) patients (44% and 7%) respect to MVD(−) (64% and 8%; p < .01). Restricting the analysis only in patients with PC and diabetes, we found that SRSF‐1(+) was associated with Ki‐67(+) (OR: 8.75; p < .05) and MVD(+) (OR: 7.5; p < .05). CONCLUSIONS: PC exhibits widespread heterogeneity in protein expression. In particular, the expressions of the SRSF‐1 protein and of the MVD are associated with a worse prognosis and in particular with a greater cell proliferation. These results, although preliminary, may offer new future scientific insights with the aim of highlighting possible genetic alterations linked to a greater expression of SRSF‐1 and associated with a worse prognosis.
format Online
Article
Text
id pubmed-8362056
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83620562021-08-17 SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study) Broggi, Giuseppe Lo Giudice, Arturo Di Mauro, Marina Asmundo, Maria Giovanna Pricoco, Elisabetta Piombino, Eliana Caltabiano, Rosario Morgia, Giuseppe Russo, Giorgio Ivan Prostate Original Articles OBJECTIVE: To study the association between insulin receptors (isoforms α and β), insulin growth factor‐1 (IGF1) and serine/arginine splicing factor 1 (SRSF‐1) in patients with prostate cancer (PC) and diabetes. MATERIALS AND METHODS: We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor‐α and ‐β, IGF1 (IGF1‐R), Ki‐67, and prostate specific membrane antigen (PSMA) expression using validated score. RESULTS: The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF‐1 expression was associated with AR (odds ratio [OR]: 1.66), PSMA (OR: 2.13), Ki‐67 (OR: 5.99), insulin receptor (IR)‐α (OR: 2.38), IR‐β (OR: 3.48), IGF1‐R (OR: 1.53), and microvascular density (MVD) was associated with PSMA (OR: 3.44), Ki‐67 (OR: 2.23), IR‐α (OR: 2.91), IR‐β (OR: 3.02), IGF1‐R (OR: 2.95), and SRSF‐1 (OR: 2.21). In the sub cohort of PC patients, we found that SRSF‐1 expression was associated with AR (OR: 2.34), Ki‐67 (OR: 6.77), IR‐α (OR: 2.7), and MVD (OR: 1.98). At the Kaplan–Meier analysis, SRSF‐1(+) patients had worse 5‐ and 9‐year biochemical recurrence (36% and 6%) respect to SRSF‐1(−) (67% and 7%; p < .01) and similarly MVD(+) patients (44% and 7%) respect to MVD(−) (64% and 8%; p < .01). Restricting the analysis only in patients with PC and diabetes, we found that SRSF‐1(+) was associated with Ki‐67(+) (OR: 8.75; p < .05) and MVD(+) (OR: 7.5; p < .05). CONCLUSIONS: PC exhibits widespread heterogeneity in protein expression. In particular, the expressions of the SRSF‐1 protein and of the MVD are associated with a worse prognosis and in particular with a greater cell proliferation. These results, although preliminary, may offer new future scientific insights with the aim of highlighting possible genetic alterations linked to a greater expression of SRSF‐1 and associated with a worse prognosis. John Wiley and Sons Inc. 2021-07-01 2021-09-01 /pmc/articles/PMC8362056/ /pubmed/34196424 http://dx.doi.org/10.1002/pros.24185 Text en © 2021 The Authors. The Prostate published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Broggi, Giuseppe
Lo Giudice, Arturo
Di Mauro, Marina
Asmundo, Maria Giovanna
Pricoco, Elisabetta
Piombino, Eliana
Caltabiano, Rosario
Morgia, Giuseppe
Russo, Giorgio Ivan
SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
title SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
title_full SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
title_fullStr SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
title_full_unstemmed SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
title_short SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)
title_sort srsf‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (diamond study)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362056/
https://www.ncbi.nlm.nih.gov/pubmed/34196424
http://dx.doi.org/10.1002/pros.24185
work_keys_str_mv AT broggigiuseppe srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT logiudicearturo srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT dimauromarina srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT asmundomariagiovanna srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT pricocoelisabetta srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT piombinoeliana srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT caltabianorosario srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT morgiagiuseppe srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy
AT russogiorgioivan srsf1andmicrovesseldensityimmunohistochemicalanalysisbysemiautomatedtissuemicroarrayinprostatecancerpatientswithdiabetesdiamondstudy